The CARE Chest X-Ray (CXR) Triage software reportedly bolsters consistent flagging of suspicious chest X-rays for lung collapse and pneumomediastinum across reviewing readers of different experience levels.
Videos
Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.
Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.
Catch up on the top radiology content of the past week.
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.
In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, offer pertinent takeaways for breast radiologists from recently issued guidelines for addressing proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
In the second of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed future directions for research on CT radiation dosing, including the potential of indication-specific diagnostic reference levels (DRLs).
In a recent episode of our Molecular Imaging in Focus series, Thomas Hope, MD, discussed challenges with conventional imaging for gliomas and the potential of the newly FDA-approved PET agent floretyrosine F18 (18F-FET) for differentiating between glioma progression and treatment-related effects.
Catch up on the top radiology content of the past week.
In a recent interview, Stamatia Destounis, MD, FACR, shared her perspective on recent changes to the BI-RADS system, offering insights on contrast-enhanced mammography, reporting changes for breast MRI and ultrasound, and the importance of auditing for BI-RADS category 3 assessments.
Catch up on the top radiology content of the past week.
In the first of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed recently published research showing significant declines in computed tomography (CT) radiation dosing over the past decade.
Offering ease of integration into existing radiology workflows, the AI-enabled Heartvue.Proton software emphasizes time savings with automation of common measurements for cardiac MRI.
In a recent episode of our Molecular Imaging in Focus series, Sharmila Dorbala, MD, MPH, discusses phase 3 study findings on the use of the PET/CT radiotracer 124I- evuzamatide for overall detection of cardiac amyloidosis as well as the subtypes light-chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) cardiac amyloidosis.
In a recent interview, Arun Talkad, MD, discussed the use of AI-powered enterprise imaging to facilitate recently expanded acute stroke care guidelines from the American Heart Association and the American Stroke Association.
Catch up on the top radiology content of the past week.
In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses the appeal of the specialty, key advances in the field in recent years, and the need for increased awareness of what interventional radiology can offer to patients.
The AI-powered software NeuroQuant PET reportedly offers automated quantification and structured reporting and facilitates evaluation of brain scans with multiple amyloid PET radiotracers.
Preliminary research with the PET radiopharmaceutical 68Ga-NYM096 has demonstrated a 95.7 percent accuracy rate in patients with primary clear cell renal cell carcinoma (ccRCC) and a significantly higher mean SUVmax in the most active lesions in comparison to 18F-FDG.
In a recent Practice Academy webinar session, Nina Kottler, MD, MS, FSIIM, FAIM, discussed challenges with narrow AI applications, the continued emergence of foundation models and a potential trajectory with AI that may facilitate a combination of opportunistic screening and prognostic risk assessment.
In a recent Practice Academy webinar session, Seena Dehkharghani, MD, FAHA, and Raza Mushtaq, MD, discussed the challenge of burgeoning worklist volume amid the ongoing radiologist shortage and the emergence of AI advances with enterprise imaging.
The cmAngio 2.0 AI-enabled software reportedly offers new capabilities for quantitative measurement of breast arterial calcification (BAC) as well as age-based contextualization based on mammography assessment.
Catch up on the latest contrast-enhanced mammography research, CT insights, MRI studies and FDA approvals in PET imaging with our Weekly Scan.
Recent positron emission tomography (PET) studies with florquinitau F 18 injection (Tauklarify) demonstrated inter-reader agreement ranging between 86 to 92 percent in evaluating patients for Alzheimer’s disease.
In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, offers her perspective on a new study that examines the effectiveness of contrast-enhanced mammography in initial and subsequent rounds of breast cancer screening.
In a recent episode of our “Molecular Imaging in Focus” series, Martin Pomper, MD, PhD, discussed the origin of PSMA PET, shared his perspective on non-PSMA targets in prostate cancer and offered his thoughts on the potential promise of emerging theranostics.
The VueJect ultrasound contrast delivery system, which is geared toward cardiac ultrasound imaging, also gained Health Canada authorization.
While reusable lead aprons are used daily throughout hospitals, they often fall outside standardized cleaning protocols. In a new webinar program, a multidisciplinary panel discusses contamination risks, ATP testing, operational barriers and the need for collaboration to strengthen environmental hygiene and reduce the risk of potential healthcare-associated infections (HAIs).
In a recent interview, Kay Jann, PhD, discussed challenges with urinary continence in stroke survivors and a forthcoming NIH-funded study examining the use of brain MRI to help identify those who may benefit from transcutaneous spinal cord stimulation (TSCS).